Company expects topline data from Phase 2b PLATEAU trial in Q4 2027.
Veru plans to prioritize internal cash for enobosarm development, focusing on the PLATEAU trial.
Overview
US biopharmaceutical firm's fiscal Q3 net loss narrowed year over year.
Company fully enrolled Phase 2b PLATEAU clinical trial for obesity, exceeding target enrollment.
Veru announced a clinical supply agreement with Novo Nordisk and received USPTO patent notice.
Result drivers
Higher R&D expenses: Research and development expenses increased to $4.4 million from $3.0 million.
Lower G&A expenses: General and administrative expenses decreased to $3.4 million from $5.0 million.
Key details and analyst coverage
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Loss Per Share
$0.30
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
VERU•
